{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:35:02Z","timestamp":1787319302066,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021204","name":"California State Library","doi-asserted-by":"publisher","award":["SC037861"],"award-info":[{"award-number":["SC037861"]}],"id":[{"id":"10.13039\/100021204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021204","name":"California State Library","doi-asserted-by":"publisher","award":["1015243"],"award-info":[{"award-number":["1015243"]}],"id":[{"id":"10.13039\/100021204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ekir.2025.103729","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:33:21Z","timestamp":1765931601000},"page":"103729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop"],"prefix":"10.1016","volume":"11","author":[{"given":"Louise","family":"Oni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hafkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Eleftheriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Keat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EMD","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evang\u00e9line","family":"Pillebout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chetwynd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areefa","family":"Alladin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cord","family":"Sunderk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Trivioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Bajema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Sanchez-Manubens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Vernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowena","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina Andreea","family":"Beldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matko","family":"Marlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagoula","family":"Gkargkoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reima","family":"Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Bogos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Brix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Anastasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen David","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Audemard-Verger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Jelusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.103729_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40620-022-01527-2","article-title":"The spectrum and changes of biopsy-proven kidney diseases in Chinese children","volume":"36","author":"He","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00281-021-00874-9","article-title":"IgA vasculitis","volume":"43","author":"Pillebout","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ekir.2025.103729_bib3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria","volume":"69","author":"Ozen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.103729_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70083","article-title":"IgA vasculitis across the ages: is it time for a precision medicine approach?","volume":"7","author":"Gage","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ekir.2025.103729_bib5","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s00467-021-04955-7","article-title":"HLA-DQ and HLA-DRB1 alleles associated with Henoch-Sch\u00f6nlein purpura nephritis in Finnish pediatric population: a genome-wide association study","volume":"36","author":"Koskela","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib6","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","article-title":"New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura)","volume":"16","author":"Heineke","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.103729_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOP.0000000000001120","article-title":"IgA vasculitis nephritis","volume":"34","author":"N\u00fcsken","year":"2022","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.ekir.2025.103729_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-020-00480-3","article-title":"Onset age is a risk factor for refractory pediatric IgA vasculitis: a retrospective cohort study","volume":"18","author":"Liao","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.ekir.2025.103729_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12969-023-00872-1","article-title":"A case series on recurrent and persisting IgA vasculitis (Henoch Schonlein purpura) in children","volume":"21","author":"Marro","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.ekir.2025.103729_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223218","article-title":"Risk factors associated with IgA vasculitis with nephritis (Henoch\u2013Sch\u00f6nlein purpura nephritis) progressing to unfavorable outcomes: a meta-analysis","volume":"14","author":"Shi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.103729_bib11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/apa.12723","article-title":"Even mild cases of paediatric Henoch-Sch\u00f6nlein purpura nephritis show significant long-term proteinuria","volume":"104","author":"Tudorache","year":"2014","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ekir.2025.103729_bib12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/rheumatology\/keae030","article-title":"IgA vasculitis nephritis-outcomes in adult-onset disease","volume":"64","author":"Stanway","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.ekir.2025.103729_bib13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","article-title":"Predictors of outcome in Henoch-Sch\u00f6nlein nephritis in children and adults","volume":"47","author":"Coppo","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.103729_bib14","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2215\/CJN.01410211","article-title":"Long-term outcome of renal transplantation patients with Henoch-Sch\u00f6nlein purpura","volume":"6","author":"Samuel","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2215\/CJN.0000000000000398","article-title":"Histologic and clinical factors associated with kidney outcomes in IgA vasculitis nephritis","volume":"19","author":"Barbour","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1 suppl 70","key":"10.1016\/j.ekir.2025.103729_bib16","first-page":"S162","article-title":"Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides","volume":"30","author":"Demirkaya","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2025.103729_bib17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2012-202111","article-title":"Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)","volume":"72","author":"Dolezalova","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.103729_bib18","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/ndt\/gfae009","article-title":"Outcome of immunosuppression in children with IgA vasculitis-related nephritis","volume":"39","author":"Rohner","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"Supplement_1","key":"10.1016\/j.ekir.2025.103729_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae069.133","article-title":"# 3108 Rituximab in adult-onset IgA vasculitis","volume":"39","author":"Trivioli","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103729_bib20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ki.2010.150","article-title":"Cesar study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein purpura","volume":"78","author":"Pillebout","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103729_bib21","article-title":"Interventions for preventing and treating kidney disease in IgA vasculitis","volume":"2","author":"Hahn","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2025.103729_bib22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.103729_bib23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103729_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis","volume":"40","author":"Vivarelli","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","article-title":"IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis","volume":"93","author":"Suzuki","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103729_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11255-021-02861-3","article-title":"Predictability of the Oxford classification of IgA nephropathy in Henoch-Schonlein purpura nephritis","volume":"54","author":"Luo","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152209","article-title":"Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: multicenter international study","volume":"61","author":"Sestan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.103729_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/0886022X.2022.2048017","article-title":"The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov","volume":"44","author":"Cui","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2025.103729_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard-2023-224946","article-title":"Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO)","volume":"83","author":"Bridgewater","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.103729_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111333","article-title":"An international modified Delphi process supported updating the web-based \u2018right review\u2019 tool","volume":"170","author":"Clyne","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ekir.2025.103729_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12882-018-1009-z","article-title":"Clinical impact of endocapillary proliferation according to the Oxford classification among adults with Henoch-Sch\u00f6nlein purpura nephritis: a multicenter retrospective cohort study","volume":"19","author":"Inagaki","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib32","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.kint.2025.07.038","article-title":"Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis","volume":"108","author":"Novak","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103729_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib34","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.103729_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/archdischild-2024-327143","article-title":"Adaptive and innovative study design in rare diseases","volume":"110","author":"Ramanan","year":"2024","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ekir.2025.103729_bib36","article-title":"IgA nephropathy: an overview of the clinical trials","volume":"7","author":"Ghozloujeh","year":"2025","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2025.103729_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2025.151650","article-title":"Integration of genetics into the design and conduct of clinical trials in nephrology","volume":"45","author":"Ozimek-Kulik","year":"2025","journal-title":"Semin Nephrol"},{"issue":"suppl 124","key":"10.1016\/j.ekir.2025.103729_bib38","first-page":"195","article-title":"Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis","volume":"38","author":"Fenoglio","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2025.103729_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102490","article-title":"Rituximab treatment for IgA vasculitis: a systematic review","volume":"19","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.103729_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103729_bib41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103729_bib42","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103729_bib43","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.103729_bib44","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103729_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.kint.2025.05.006","article-title":"Zigakibart demonstrates clinical safety and efficacy in a Phase 1\/2 trial of healthy volunteers and patients with IgA nephropathy","volume":"108","author":"Kooienga","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103729_bib47","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103729_bib48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib49","unstructured":"Atacicept in multiple glomerular diseases. ClinicalTrials.gov identifier: NCT06983028. Updated July 24, 2024. Accessed 17 June 2025. https:\/\/clinicaltrials.gov\/study\/NCT06983028."},{"key":"10.1016\/j.ekir.2025.103729_bib50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 trial of Telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.103729_bib51","unstructured":"WCG CenterWatch. Clinical study on the efficacy and safety of Telitacicept in the treatment of pediatric IgA nephropathy or IgA vasculitis nephritis. CenterWatch. ClinicalTrials.gov identifier: NCT07052981. Updated July 06, 2025. Accessed 17 June 2025. https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT07052981\/clinical-study-on-the-efficacy-and-safety-of-telitacicept-in-the-treatment-of-pediatric-iga-nephropathy-or-iga-vasculitis-nephritis"},{"key":"10.1016\/j.ekir.2025.103729_bib52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced Dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2025.103729_bib53","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/rheumatology\/kew286","article-title":"Successful outcome using bortezomib in adult refractory IgA vasculitis: a case report","volume":"55","author":"Van de Perre","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.103729_bib54","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.103729_bib55","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib56","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.103729_bib57","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib58","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a Phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.103729_bib59","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103729_bib60","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.103729_bib61","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.103729_bib62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of Cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib63","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a Phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103729_bib64","unstructured":"Study of ravulizumab in pediatric participants with primary IgAN. ClinicalTrials.gov identifier: NCT07024563. Updated August 26, 2025. Accessed 17 June 2025. https:\/\/clinicaltrials.gov\/study\/NCT07024563."},{"key":"10.1016\/j.ekir.2025.103729_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152876","article-title":"Inhibiting the alternative pathway of complement by reducing systemic complement factor B: randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen","volume":"230","author":"McCaleb","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.ekir.2025.103729_bib66","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.103729_bib67","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103729_bib68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10067-017-3568-y","article-title":"Multicentric Castleman\u2019s disease associated with IgA vasculitis (Henoch-Sch\u00f6nlein purpura) responding well to tocilizumab: a case report","volume":"36","author":"Oshima","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2025.103729_bib69","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.2147\/DDDT.S383138","article-title":"Insights on Nefecon\u00ae, a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy","volume":"18","author":"Barratt","year":"2024","journal-title":"Drug Des Devel Ther"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:34:58Z","timestamp":1773963298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925007478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2468024925007478"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103729","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103729"}}